增殖性糖尿病视网膜病的治疗方案及疗效

目的：探讨增殖性糖尿病视网膜病的治疗方案及疗效。方法将46例增殖性糖尿病视网膜病患者分为观察组与对照组各23例。两组患者均给予玻璃体切除术治疗，观察组于术前5 d在玻璃体腔内注射1．5 mg贝伐单抗，术后在玻璃体腔内注射1 mg曲安耐德；对照组仅进行玻璃体切除术。结果观察组平均手术时间、术中出血发生率、医源性视网膜裂孔发生率分别是（109．5±14．2）min、8．70％、4．35％，均低于对照组，差异均有统计学意义（ P＜0．05）；观察组瞳孔区膜性渗出、复发玻璃体积血及视网膜新生血管膜再增生发生率分别为4．35％、0．00％、0．00％，均低于对照组，差异均有统计学意义（ P＜0．05）；观察组于术后3周时眼压恢复正常，对照组在术后1个月时恢复正常，两组患者术后视力改善及视网膜复位情况差异均无统计学意义（P＞0．05）。结论两组治疗方案对患者术后视力恢复及视网膜复位情况无显著影响，于术前及术后注射药物之后，显著缩短了手术时间，降低了术中及术后并发症发生率，减少了手术风险。

Effect of preoperative injection of bevacizumab on proliferative diabetic retinopathy

Objective To explore treatment options and effect of pertile diabetic retinopathy .Methods Forty-six patients with proliferative diabetic were selected and divided into observation group and control group （n=23） by the table of random numbers method .Patients in observation group injected into vitreous with 1 .5 mg bevacizumab at the fifth days before operation ,injected with 1 mg song Ann Snyder after operation ;the control group ,only accepted vitreous resection .Results The mean operation time ,blood loss ,the incidence of iatrogenic retinal breaks of the ob-served group were （109 .5 ± 14 .2）min ,8 .70% ,4 .35% ,all lower than those of the control group significant （P0 .05） .Conclusion Different treatment programs for patients have the same effect ,but injecting drugs before and after operation will reduce surgery time ,intraoperative and postoperative complication rates ,so decrease surgical risk .